Antiretroviral-based microbicides applied topically to the vagina may play an important role 24 in protecting women from HIV infection. Incorporation of the nucleoside reverse transcriptase 25 inhibitor tenofovir (TFV) into intravaginal rings (IVRs) for sustained mucosal delivery could 26 lead to increased microbicide product adherence and efficacy when compared with conventional 27 vaginal formulations. Formulations of a novel "pod IVR" platform spanning a range of IVR drug 28 loadings and daily release rates of TFV were evaluated in a pig-tailed macaque model. The rings 29
In CAPRISA 004, participants who were instructed to use a peri-coital vaginal gel containing 51 1% tenofovir (TFV) showed a 39% reduction in HIV transmission compared to those receiving 52 placebo gel (20) . In late November 2011, the Data and Safety Monitoring Board of the VOICE 53 trial, a major HIV prevention study in women that included a TFV vaginal gel component 54 (http://www.mtnstopshiv.org/node/3909), issued a statement on the decision to discontinue the 55 use of the TFV gel due to lack of efficacy. While the reasons underlying these different 56 outcomes remain to be elucidated, they highlight the pressing need for an improved 57 understanding of the fundamental processes affecting efficacy. six sexually mature female pig-tailed macaques (Macaca nemestrina) were used; four received 136 medicated IVRs (Table 1) , and two received blank control IVRs The second study, PK2 (Jul. 137 2010), used three sexually mature female pig-tailed macaques receiving medicated IVRs 138 according to the characteristics shown in Table 1 . The third study, PK3 (Jul. 2011), consisted of 139 a terminal PK study and used two SHIV-infected, sexually mature female pig-tailed macaques 140 with medicated IVRs (Table 1) . SHIV-infected macaques released from previous efficacy studies 141
were used in PK3 since this study needs to be terminal in order to furnish sufficient vaginal 142 tissue for the detection of intracellular TFV-DP levels in tissue monocytes. While it is 143 acknowledged that the inclusion of only two animals impacts the statistical significance of the 144 data, it is currently the only feasible experimental approach, as supported by other reports (6), 145 because of the low availability of infected macaques. The IVRs were inserted on Day 0 into the 146 posterior vagina and retained for a period of 28 days for PK1 and PK2, and 14 days for PK3. (size 5 or 8 French) of adjusted length and CVL was drawn out with the same device. The CVL 158 was observed for the presence of blood or any other discoloration. In the non-terminal study 159 (PK1), tissue collection consisted of vaginal biopsies. In the terminal study (PK3), the animals 160 were necropsied on day 14 and the vaginal tissue obtained was sectioned into three areas; 161 proximal, medial, and distal vaginal segments relative to the location of the IVR. Animals were 162 sedated when procedures are performed and, after recovery from anesthesia, the animals are 163 awake and mobile in their cages. Animal enrichment procedures are in place to promote the 164 health and well-being of the animals. 165
Blood and CVL were obtained up to three weeks prior to the insertion of the ring in order to 166 establish baseline cytokine profiles. Amicon ultra-4 10 KDa concentrators (Millipore, Billerica, 167 MA) were used to concentrate the CVL washes for cytokine analysis. Induction of mucosal The TFV lower limits of quantitation (LLOQs) for CVL and plasma were 5 and 7 ng mL -1 , 208 respectively, and 15 ng g -1 in tissue samples. The intracellular TFV-DP LLOQ was 10 ng mL -1
209
(6, 25), which corresponds to 13 fmol (10 6 cells) -1 (25). All calibration curves had R 2 values 210 greater than 0.99. 211
RESULTS 212
In vitro studies. In vitro cumulative release profiles for the three IVR formulations exhibited 213 linear (R 2 > 0.95) sustained release of TFV over the course of the studies, as is typical for pod-214
IVRs (4, 29-30). The cumulative release rates over these time periods are shown in Table 2 . 215 Nonhuman primate studies: safety profiles. No ring expulsions or behavioral changes were 216 noted throughout all studies, and adverse effects were not observed by colposcopy. Cytokine 217 profiles, both locally and systemically, were stable when samples collected before and after ring 218 removal were compared to when the ring was in place and releasing drug (Fig. 3) . The 219 proinflammatory cytokines TNFα, IL-1β, MIP-1α, IL-8, and MIP-1β were all unchanged in the 220 local mucosal environment and no increases were observed systemically in the plasma. 221
Details on the impact of the IVRs in PK1 on vaginal microflora have been presented 222 elsewhere (13), and only a brief discussion is included below. The ring surfaces were covered 223 with monolayers of epithelial cells. Two bacterial biofilm phenotypes were found to develop on 224 on November 3, 2017 by guest http://aac.asm.org/ Downloaded from 11 these monolayers and both had a broad diversity of bacterial cells closely associated with the 225 extracellular material (13). These structures did they appear to impact the IVR release rates 226
significantly. 227
In vitro-in vivo correlation (IVIVC). IVIVC was analyzed to describe a framework that 228 minimizes in vivo studies required in future research. In vitro experiments therefore may guide 229 parameter selection in the development of sustained release formulations. The calculated IVIVC 230 for PK1 and PK2 is given in Table 2 and indicate that release rates in vivo are ca. 5 times as fast 231 as those measured in vitro. Note that the in vivo release rate for PK1 is biased low because the 232 complete 12 mg drug payload was delivered in less than 28 days, according to residual drug 233 measurements on the used IVRs. No IVIVC is presented for PK3 as this study was designed to 234 have most of the drug delivered in the first 7 days of the study (see Discussion). 235
Nonhuman primate studies: pharmacokinetics. Drug distribution and concentrations 236
across key pharmacokinetic compartments are summarized in Table 3 . Cervicovaginal lavage 237 (CVL) TFV levels for all three studies are shown in Figure 4 , and vaginal secretion TFV 238 concentrations are shown in Figure 5 . While TFV levels in CVL and vaginal secretion samples 239 were poorly correlated (R 2 = 0.079 and 0.007 for secretions collected proximally and distally to 240 the IVRs, respectively), the mean values in PK2 suggest that, on average, a 22-fold dilution of 241 the vaginal fluid results from the lavage procedure: mean secretion levels over the vaginal tract 242 in PK2, 72.4 ± 109 µg mL -1 ; mean CVL levels in PK2, 3.31 ± 2.59 μg mL -1 (Table 3) (Table 2) . Finally, controlled and sustained release is independent of the ring 274 material, which acts as a scaffold to hold the pods, offering flexibility in drug and polymer 275 choice that may be important for future large-scale production. 276
The development of IVR formulations to deliver antiretroviral active pharmaceutical 277 ingredients (APIs) for HIV prevention will have to follow the guiding principles of microbicide 278 design in being effective, well-tolerated, user-friendly, and affordable (17, 23). In a recent review 279 on IVR technology for topical HIV prophylaxis Kiser and colleagues state that, "the academic 280 drug-delivery community often overlooks practical issues such as API chemical and physical 281 stability, cost and reproducibility, and manufacturability, all of which should be seriously 282 considered when designing drug-delivery devices for use in the developing world" (22). The 283 modular design of the pod-IVR is key to enabling cost-effective manufacturability, which is 284 accomplished in three major steps: (i) injection molding of empty ring using established and 285 inexpensive injection molding processes and with no API present, unlike conventional 286 technologies where the API is dispersed in the ring polymer (27); (ii) core tableting and polymer 287 coating -identical to the production method for tablet-based oral dosage forms, a mature 288 technology; and (iii) IVR assembly, which can be accomplished manually at first and using 289 automation at higher production volumes. The only API-dependent manufacturing step in this Local safety of the IVRs. Local inflammation is a concern when devices are inserted in a 294 body compartment for extended periods of time. Mucosal levels of the proinflammatory 295 cytokines TNFα, IL-1β, MIP-1α, IL-8 and MIP-1β remained stable throughout the study period 296 in all animals with no significant increases observed as a result of the IVRs (Fig. 3) . The only 297 statistically significant changes observed were a slight decrease in IL-6, RANTES, and IL-1Ra. 298
In addition, there were no changes observed in systemic cytokine patterns. This is typical and has 299 been observed previously in pig-tailed macaques involving IVRs (37). The vaginal microflora 300 was undisturbed as a result of the IVRs during the course of the study (13). One of the control 301 animals developed BV-like flora following insertion of the IVR, evidenced by a drop in H 2 O 2 302 producing bacterial populations and a concomitant infection by Gardnerella vaginalis, which 303 subsided after the IVR was removed. The microbial biofilm communities that developed on the 304 IVR surfaces did not lead to any observable, negative local toxicity outcomes (13). 305
Drug distribution and concentration. Figures 4 and 5 demonstrate that sustained release of 306
TFV, exemplified by steady state drug levels, was achieved over the course of both studies. The 307 CVL TFV levels from PK1 (mean 3.98 ± 3.02 μg mL -1 ) and PK2 (mean 3.31 ± 2.59 μg mL -1 ) 308 were statistically similar, based upon a naïve analysis comparing means and standard deviations 309 on the means, despite the fact that the second set of IVRs contained five times as much drug, but 310 were designed to have the same release profiles. Steady state TFV concentrations in vaginal 311 secretions (Table 3) (Table 2) . Mean TFV levels in vaginal secretions and tissue were 315 not correlated with the sampling location, i.e., proximal and distal to the IVR (Table 3) the drug to rectal tissue lymphocytes, with a twenty-fold decrease in intracellula TFV-DP levels 336 relative to vaginal tissue lymphocytes (Table 3) . Similar results were obtained by Nuttall et al. 337 on November 3, 2017 by guest http://aac.asm.org/ Downloaded from using TFV gel formulations in rhesus macaques, although these investigators were unable to 338 detect the intracellular phosphorylated moiety (32). These data suggest that a TFV-based 339 microbicide applied vaginally may hold potential for protecting against rectal exposure to HIV-1. 340
Systemic TFV levels were below the 7 ng mL -1 LLOQ in all studies, a benefit of the topical, 341 sustained release delivery system as it avoids the large peaks and troughs characteristic of oral-342 and gel-based formulations. 343
While TFV concentrations in vaginal secretions decreased sharply after the removal of the 344 IVR (Fig. 5) , tissue levels remained at steady state ( 
